<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03017378</url>
  </required_header>
  <id_info>
    <org_study_id>VIT-I-01/2013</org_study_id>
    <nct_id>NCT03017378</nct_id>
  </id_info>
  <brief_title>Reactogenicity, Safety and Immunogenicity of a TB/FLU-01L Tuberculosis Vaccine</brief_title>
  <official_title>A Randomized, Open Clinical Trial Phase 1 Vaccine TB/FLU-01L by Intranasal and Sublingual Application for Specific Immunotherapy Pulmonary Tuberculosis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Research Institute for Biological Safety Problems</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Tuberculosis Problems, Kazakhstan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Research Institute of Influenza, Russia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Research Institute for Biological Safety Problems</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is a single centre, phase I, open, randomized, by intranasal and sublingual
      application trial that explored the safety and immunogenicity of 2 doses (Day 1 and Day 21)
      TB/FLU-01L tuberculosis vaccine in BCG-vaccinated healthy adult subjects aged 18-50 years.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Actual">February 2015</completion_date>
  <primary_completion_date type="Actual">April 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events (AE) - Immediate reactions</measure>
    <time_frame>Two hours</time_frame>
    <description>Commonly Solicited Local reactions associated with injections: pain, erythema/redness, swelling, induration, bruising at the injection site.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Solicited local and systemic reactions</measure>
    <time_frame>Greater than 2 hours after administration of any dose of vaccine through 7 days following any dose</time_frame>
    <description>Commonly Solicited general symptoms: fever (oral temperature ≥ 38.0°C), chills, muscle aches/myalgia, arthralgia, fatigue, malaise, headache, rash, sweating, nausea, vomiting, diarrhea and potential indicators of oculo-respiratory syndrome* (ORS).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Unsolicited AEs</measure>
    <time_frame>Greater than 2 hours after administration of any dose of vaccine or placebo through 7 days following any dose</time_frame>
    <description>Unsolicited AEs are any untoward medical occurrence in the subject, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Serious adverse events (SAEs), including abnormal laboratory findings</measure>
    <time_frame>Three weeks of receipt of any dose</time_frame>
    <description>Serious adverse events (SAEs) are medical occurrences that result in death, are life threatening, require hospitalization or prolongation of hospitalization, result in disability/incapacity or are a congenital anomaly/birth defect in the offspring of a study subject.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Tuberculosis</condition>
  <arm_group>
    <arm_group_label>TB/FLU-01L (intranasal application)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccine safety analysis of TB/FLU-01L at double intranasal application in healthy volunteers aged 18 to 50 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TB/FLU-01L (sublingual application)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Vaccine safety analysis of TB/FLU-01L at double sublingual application in healthy volunteers aged 18 to 50 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TB/FLU-01L</intervention_name>
    <description>TB / FLU-01L (intranasal application)</description>
    <arm_group_label>TB/FLU-01L (intranasal application)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>TB/FLU-01L</intervention_name>
    <description>TB/FLU-01L (sublingual application)</description>
    <arm_group_label>TB/FLU-01L (sublingual application)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy BCG-vaccinated male or female adult 18 through 50 years of age at the
             enrollment visit.

          -  Literate and willing to provide written informed consent.

          -  A signed informed consent.

          -  Capable and willing to complete diary cards and willing to return for all follow-up
             visits.

          -  For females, willing to take reliable birth control measures throughout the entire
             period of participation in the study

        Exclusion Criteria:

          -  Clinical, radiological (chest X-ray) or laboratory evidence of active or past TB
             disease.

          -  Current or past administration of anti-TB therapy.

          -  History of contact with TB patients.

          -  Positive QuantiFERON-TB Gold test.

          -  BCG vaccination in less than 6 months prior to study.

          -  Practice of nasal irrigation on a regular basis within the past six months or has
             engaged in nasal irrigation within two weeks prior to enrollment.

          -  Recent history of frequent nose bleeds (&gt;5 within the past year).

          -  Clinically relevant abnormal paranasal anatomy.

          -  Recent history (within the past month) of rhino or sinus surgery, or surgery for any
             traumatic injury of the nose.

          -  Current or recent (within two weeks of enrollment) acute respiratory illness with or
             without fever.

          -  Hypersensitivity after previous administration of any vaccine.

          -  History of chronic alcohol abuse and/or illegal drug use.

          -  Any clinically significant abnormal laboratory finding.

          -  A positive pregnancy test for all women of childbearing potential.

          -  Administration of immunosuppressive drugs or other immune modifying drugs within 4
             weeks prior to study enrollment.

          -  Acute or chronic clinically significant pulmonary disease, cardiovascular disease,
             gastrointestinal disease, liver disease, neurological illness, liver disease, blood
             disease, skin disorder, endocrine disorder, neurological illness and psychiatric
             disorder as determined by medical history, physical examination or clinical laboratory
             screening tests, which in the opinion of the investigator, might interfere with the
             study objectives.

          -  History of leukemia or any other blood or solid organ cancer.

          -  Seropositive for HIV, hepatitis B surface antigen and/or hepatitis C antibodies.

          -  Receipt of antivirals, antibiotics, immunoglobulins or other blood products within 4
             weeks prior to study enrollment or planned receipt of such products during the period
             of subject participation in the study.

          -  Participation in another clinical trial within the previous three months or planned
             enrollment in such a trial during the period of this study.

          -  Subjects who are, in the opinion of the investigator, at significantly increased risk
             of non-cooperation with requirements of the study protocol.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Berik M Khairullin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Research Institute for Biological Safety Problems</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Center for Tuberculosis Problems, Kazakhstan</name>
      <address>
        <city>Almaty Qalasy</city>
        <state>Almaty</state>
        <zip>050000</zip>
        <country>Kazakhstan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Kazakhstan</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 4, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 11, 2017</study_first_posted>
  <last_update_submitted>January 10, 2017</last_update_submitted>
  <last_update_submitted_qc>January 10, 2017</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>influenza vector</keyword>
  <keyword>tuberculosis</keyword>
  <keyword>vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tuberculosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

